GlassScriptPhysician profile
Julia K Phillips
NPI 1720341779
$6,101.59
in general payments reported to CMS, 2019-2025
34 companies · $909 in 2025
The $909 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $240 · 2021: $802 · 2022: $1,196 · 2023: $1,506 · 2024: $938 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,353.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,279.77 | 2019-2025 | Ubrelvy, Lo Loestrin Fe, Qulipta |
| Evofem Biosciences, INC. | $657.87 | 2021-2025 | Phexxi, Solosec, Phexx |
| Mayne Pharma Commercial LLC | $554.48 | 2021-2025 | |
| Astellas Pharma US INC | $347.27 | 2022-2025 | Veozah, Myrbetriq |
| Amgen INC. | $267.57 | 2020-2023 | Evenity, Prolia |
| Hologic Sales and Service, LLC | $259.22 | 2019-2025 | Thinprep 2000 Processor, Aptima, Third Wave |
| Sage Therapeutics, LLC | $253.20 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $219.33 | 2019-2025 | |
| Acera Surgical, INC. | $208.63 | 2025 | Restrata Wound Matrix |
| Bayer Healthcare Pharmaceuticals INC. | $188.10 | 2019-2025 | |
| Organon LLC | $179.15 | 2021-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $174.14 | 2023-2025 | Myfembree, Gemtesa |
| Allergan, INC. | $161.03 | 2019-2020 | |
| Agile Therapeutics, INC. | $136.14 | 2021-2024 | Twirla |
| Novo Nordisk INC | $128.76 | 2020-2024 | Wegovy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $122.89 | 2022-2023 | Tymlos |
| Idorsia Pharmaceuticals US INC | $110.61 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $93.01 | 2023-2025 | Cologuard Collection Kit |
| Myovant Sciences INC. | $85.55 | 2021-2022 | |
| Exeltis, USA INC. | $82.54 | 2023-2025 | Slynd |
| Therapeuticsmd, INC. | $79.56 | 2019-2022 | |
| Meditrina | $78.85 | 2022-2023 | |
| Lupin INC. | $65.38 | 2019-2021 | |
| Mission Pharmacal Company | $60.27 | 2019-2020 | |
| Avion Pharmaceuticals | $52.80 | 2022-2023 | Balcoltra |
| Ethicon US, LLC | $39.59 | 2024 | Dermabond |
| Shield Therapeutics INC | $39.10 | 2022 | |
| Millicent US INC | $38.10 | 2024-2025 | Intrarosa, Femlyv |
| Merck Sharp & Dohme LLC | $29.51 | 2019-2024 | Gardasil 9, Gardasil |
| Vertical Pharmaceuticals, LLC | $28.04 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.53 | 2022 | |
| Covidien LP | $22.60 | 2019 | |
| Optumhealth Care Solutions, LLC | $19.26 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Scynexis, INC. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.